Ex Vivo Priming of Naïve T Cells Into EBV-Specific Th1/Tc1 Effector Cells by Mature Autologous DC Loaded with Apoptotic/Necrotic LCL

American Journal of Transplantation

Volumn 3, Issue 11, 2003, Pages 1369-1377

  Popescu, Iulia ^a   Macedo, Camila ^a   Zeevi, Adriana ^a,b   Nellis, Joseph ^a   Patterson, Kevin R ^a   Logar, Allison ^a   Rowe, David ^c   Reyes, Jorge ^a   Rao, Abdul S ^d   Storkus, Walter J ^a   Fung, John J ^a   Metes, Diana ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cytotoxicity; EBV; HLA peptide tetramer probes; IFN

Indexed keywords

BETA1 INTEGRIN; CD4 ANTIGEN; CD69 ANTIGEN; CD8 ANTIGEN; EPITOPE; PADGEM PROTEIN; RECOMBINANT INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; NECROSIS; NORMAL HUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PROPHYLAXIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ANTIGEN PRESENTATION; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; L-SELECTIN; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; LYMPHOPROLIFERATIVE DISORDERS; MONOCYTES; NECROSIS; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TIME FACTORS;

EID: 0142027131     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00252.x     Document Type: Article

References (33)

1. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999; 170: 49-64.
2. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol 1999; 11: 96-101.
3. Rooney CM, Aguilar LK, Huls MH, Brenner MK, Heslop HE. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol 2001; 258: 221-229.
4. Lucas KG, Pollok KE, Emanuel DJ. Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 1997; 25: 1-8.
5. Metes D, Storkus W, Zeevi A et al. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation 2000; 70: 1507-1515.
6. Metes D, Storkus WJ, Zeevi A et al. Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV (-) individuals. Transplant Proc 2001; 33: 441.
7. Savoldo B, Cubbage ML, Durett AG et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol 2002; 168: 909-918.
8. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand J Immunol 1991; 34: 697-712.
9. Rowe DT, Qu L, Reyes J et al. Use of quantitative competitive PCR to measure Epstein-Barr Virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Micro 1997; 35: 1612-1615.
10. Bunce M, O'Neal C, Barnardo M, Morris P, Welsh K. Comprehensive DNA typing for HLA-A, B. C, DRB3, DRB4, DRB5 and DQB1 by PCR and 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355-367.
11. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431.
12. Romani N, Reider D, Heuer M et al. Generation of mature DC from human blood: an improved method with special regard to clinical applicability. J Immunol Meth 1996; 196: 137-151.
13. Zarour H, Kirkwood JM, Kierstead LS et al. MART-1 51-37 represents an immunogenic HLA-DR4 restricted epitope recognized by melanoma-reactive CD4+ T cells. Proc Natl Acad Sci U S A 2000; 97: 400-405.
14. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148: 2207-2216.
15. Jonuleit H, Knop J, Enk AH. Cytokines and their effects on maturation, differentiation and migration of dendritic cells. Arch Dermatol Res 1996; 289: 1-8.
16. 5, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359-1368.
17. Tatsumi T, Kierstead LS, Ranieri E et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4 (+) T cell responses against MAGE-6 in HLA-DRB10401(+)patients with renal cell carcinoma or melanoma. J Exp Med 2002; 196: 619-628.
18. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
19. Sallusto F, Lanzavecchia A. Exploring pathways for memory T cell generation. J Clin Invest 2001; 108: 805-806.
20. Hislop AD, Gudgeon NH, Callan MF et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001; 167: 2019-2029.
21. Catalina MD, Sullivan JL, Brody RM, Luzuriaga K. Phenotypic and functional heterogeneity of EBV epitope-specific CD8+ T cells. J Immunol 2002; 168: 4184-4191.
22. Bhardwaj N, Seder RA, Reddy A, Feldman MV. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest 1996; 98: 715-722.
23. Gherardi MM, Ramirez JC, Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 2001; 16: 655-667.
24. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997; 185: 1605-1617.
25. Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Munz C. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8 (+) killer T cells. J Exp Med 2001; 193: 405-411.
26. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8 (+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195: 893-905.
27. Faint JM, Annels NE, Curnow SJ et al. Memory T cells constitute a subset of the human CD8+; CD45RA:+ pool with distinct phenotypic and migratory characteristics. J Immunol 2001; 167: 212-220.
28. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000; 290: 92-97.
29. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68: 106-166.
30. Tanner JE, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 2: 60-69.
31. Falco DA, Nepomuceno RR, Krams SM et al. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 2002; 74: 501-510.
32. Munz C, Bickham KL, Subklewe M et al. Human CD4 (+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191: 1649-1660.
33. Leen A, Meij P, Redchenko I et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 2001; 75: 8649-8659.